11Feb 2025
Irbesartan Cuts Arterial Event Risk in Ehlers-Danlos Syndrome

Irbesartan Cuts Arterial Event Risk in Ehlers-Danlos Syndrome

A randomized, placebo-controlled trial assessed the efficacy of irbesartan in patients with vascular Ehlers-Danlos syndrome on stable celiprolol therapy. The primary composite outcome, including arterial events and new or worsening lesions, occurred in 27.6% of irbesartan-treated patients versus 53.6% of placebo recipients (hazard ratio, 0.42; P<0.05). Irbesartan significantly reduced systolic blood pressure and arterial lesion progression. However, 11 cases of hypotension led to dose adjustments.

  • #cardiology

Like

Save

Share